An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate (ORAL STRATEGY)

May 29, 2018 updated by: Pfizer

A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis

To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes measures in the study. To evaluate the safety and tolerability of tofacitinib and adalimumab. To evaluate the safety of the zoster vaccine given prior to the initiation of tofacitinb or adalimumab.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

1152

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina, 1015
        • Organizacion Medica de Investigacion S.A - OMI
      • San Juan, Argentina, 5400
        • Cer San Juan, Centro Polivalente de Asistencia e Investigacion Clinica
    • Buenos Aires
      • Caba, Buenos Aires, Argentina, C1426AAL
        • Atencion Integral en Reumatologia (AIR)
    • Tucuman
      • San Miguel de Tucuman, Tucuman, Argentina, 4000
        • Centro Medico Privado de Reumatologia
      • San Miguel de Tucuman, Tucuman, Argentina, 4000
        • Centro Radiologico Luis Mendez Collado SRL
  • Australia
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Royal Prince Alfred Hospital
    • Queensland
      • Southport, Queensland, Australia, 4215
        • Pacific Private Clinic
      • Southport, Queensland, Australia, 4215
        • QML Pathology
    • South Australia
      • Woodville South, South Australia, Australia, 5011
        • The Queen Elizabeth Hospital
    • Victoria
      • Malvern East, Victoria, Australia, 3145
        • Emeritus Research
    • Western Australia
      • Victoria Park, Western Australia, Australia, 6100
        • RK Will Pty Ltd
  • Bosnia and Herzegovina
      • Tuzla, Bosnia and Herzegovina, 75000
        • University Clinical Center Tuzla
    • Republika Srpska
      • Banja Luka, Republika Srpska, Bosnia and Herzegovina, 78000
        • University Hospital Clinical Center Banja Luka
  • Bulgaria
      • Pleven, Bulgaria, 5800
        • UMHAT "Dr. Georgi Stranski" EAD
      • Plovdiv, Bulgaria, 4002
        • MHAT "Kaspela" EOOD
      • Plovdiv, Bulgaria, 4004
        • MHAT EUROHOSPITAL Plovdiv
      • Ruse, Bulgaria, 7002
        • MHAT Ruse AD
      • Ruse, Bulgaria, 5400
        • MHAT Akta Medika OOD
      • Shumen, Bulgaria, 9700
        • MHAT Shumen AD
      • Sofia, Bulgaria, 1336
        • MHAT Lyulin EAD
      • Sofia, Bulgaria, 1233
        • NMTH Tsar Boris Clinic of Internal Diseases
      • Targovisthe, Bulgaria, 7700
        • MHAT "Targovishte" AD
  • Canada
    • Ontario
      • Kitchener, Ontario, Canada, N2M 5N6
        • Kw Musculoskeletal Research Inc
    • Quebec
      • Trois-Rivieres, Quebec, Canada, G8Z 1Y2
        • Centre De Recherche Musculo-Squelettique
  • Chile
    • Metropolitana
      • Santiago, Metropolitana, Chile, 7510047
        • Prosalud
    • Valparaiso
      • Vina del Mar, Valparaiso, Chile, 2520997
        • Estudios Clinicos Quinta Region Ltda.
    • X Region
      • Puerto Varas, X Region, Chile, 5550170
        • Quantum Research Ltda
      • Puerto Varas, X Region, Chile, 5550170
        • Quantum Research
  • Czechia
      • Brno, Czechia, 63800
        • Revmatologie s.r.o.
      • Ceska Lipa, Czechia, 470 01
        • Revmatologicka ambulance
      • Ostrava- Moravska Ostrava, Czechia, 702 00
        • Vesalion, s.r.o.
      • Praha 4, Czechia, 140 00
        • Revmatologie
    • Czech Republic
      • Brno - Zidenice, Czech Republic, Czechia, 615 00
        • Revmacentrum MUDr. Mostera, s.r.o.
  • Estonia
      • Parnu, Estonia, 80010
        • Foundation Parnu Hospital
      • Tallinn, Estonia, 13419
        • North Estonia Medical Centre Foundation
      • Tallinn, Estonia, 11312
        • East-Tallinn Central Hospital Ltd
  • Israel
      • Haifa, Israel, 3109601
        • Rambam Health Care Campus
      • Haifa, Israel, 31048
        • Bnai Zion Medical Center
      • Jerusalem, Israel, 91120
        • Hadassah Medical Center
      • Tel-Hashomer, Israel, 5262000
        • The Chaim Sheba Medical Center
  • Korea, Republic of
      • Daegu, Korea, Republic of, 41944
        • Kyungpook National University Hospital
      • Daegu, Korea, Republic of, 42472
        • Daegu Catholic University Medical Center
      • Gwangju, Korea, Republic of, 61469
        • Chonnam National University Hospital
      • Seoul, Korea, Republic of, 05030
        • Konkuk University Medical Center
      • Seoul, Korea, Republic of, 04763
        • Hanyang University Seoul Hospital
    • Incheon
      • Jung-Gu, Incheon, Korea, Republic of, 22332
        • Inha University Hospital
  • Latvia
      • Riga, Latvia, LV-1012
        • Health Center 4
      • Riga, Latvia, LV1005
        • Orto Clinic Ltd
  • Lithuania
      • Alytus, Lithuania, LT-62114
        • Alytaus District S. Kudirkos Hospital
      • Kaunas, Lithuania, LT-50128
        • VAKK "Clinic of Dr. Kilda"
      • Siauliai, Lithuania, LT-76231
        • PI Republican Siauliai Hospital
  • Mexico
      • Chihuahua, Mexico, 31000
        • Investigacion y Biomedica de Chihuahua, SC
      • Jalisco, Mexico, 44160
        • Centro de Integral en Reumatologia SA de CV
      • San Luis Potosi, Mexico, 78213
        • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, S.C.
      • San Luis Potosi, Mexico, 78290
        • Unidad de Investigaciones Reumatologicas A.C.
    • Coahuila
      • Torreon, Coahuila, Mexico, 27000
        • Unidad de Enfermedades Reumaticas y Cronico Degenerativas S. C.
    • Distrito Federal
      • Mexico, Distrito Federal, Mexico, 11850
        • CINTRE, Centro de Investigacion y Tratamiento Reumatologico S.C. Consultorio Medico de Reumatologia
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44160
        • Centro Integral en Reumatologia, SA de CV
    • Sinaloa
      • Culiacan, Sinaloa, Mexico, 80000
        • Centro de Investigacion de Tratamientos Innovadores de Sinaloa S.C.
      • Culiacan, Sinaloa, Mexico, 80000
        • Centro de Investigacion en Tratamientos Innovadores de Sinaloa S.C.
    • Yucatan
      • Merida, Yucatan, Mexico, 97133
        • Centro Multidisciplinario para el Desarrollo Especializado de la Invetigacion Clinica en Yucatan
      • Merida, Yucatan, Mexico, 97133
        • Departamento de Imagen de Hospital Star Medica Merida
      • Merida, Yucatan, Mexico, 97133
        • Laboratorio clínico del Hospital Star Medica Merida
      • Merida, Yucatan, Mexico, 97133
        • Storage for lab kits and study materials
  • Peru
      • Arequipa, Peru, 04020
        • Unidad de Investigacion en Medicina Interna y Enfermedades criticas-Hogar Clinica San Juan de Dios
      • Lima, Peru, 33
        • Investigaciones Clinicas S.A.C.
      • Lima, Peru, 21
        • ABK REUMAR S.R.L. de Medicentro Biociencias_ BIO CIENCIAS PERU S.R.L.
      • Lima, Peru, 27
        • Instituto Peruano del Hueso y la Articulación
  • Philippines
      • Cebu City, Philippines, 6000
        • Perpetual Succour Hospital
      • Davao, Philippines, 8000
        • Davao Doctors Hospital
      • Iloilo City, Philippines, 5000
        • St. Paul's Hospital of Iloilo, Inc.
    • Batangas
      • Lipa City, Batangas, Philippines, 4217
        • Mary Mediatrix Medical Center
    • Davao DEL SUR
      • Davao, Davao DEL SUR, Philippines, 8000
        • Brokenshire Integrated Health Ministries, Inc.
    • Iloilo
      • Iloilo City, Iloilo, Philippines, 5000
        • Iloilo Doctors' Hospital, Inc
    • Metro Manila
      • Manila, Metro Manila, Philippines, 1000
        • University of the Philippines Manila-Philippine General Hospital
      • Manila, Metro Manila, Philippines, 1003
        • Jose R. Reyes Memorial Medical Center-Rayuma Klinik
      • Quezon City, Metro Manila, Philippines, 1102
        • St. Luke's Medical Center
      • Quezon City, Metro Manila, Philippines, 1118
        • Far Eastern University - NRMF Medical Center
  • Poland
      • Bydgoszcz, Poland, 85-168
        • Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy,
      • Bytom, Poland, 41-902
        • Nzoz Bif-Med
      • Bytom, Poland, 41-902
        • Centrum Medyczne SILESIANA Sp. z o.o.
      • Elblag, Poland, 82-300
        • Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka
      • Gdynia, Poland, 81-384
        • Synexus Polska Sp. z o.o. Oddzial w Gdyni
      • Katowice, Poland, 40-040
        • Synexus Polska Sp. Z O.O. Oddzial W Katowicach
      • Lodz, Poland, 90-242
        • Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
      • Nadarzyn, Poland, 05-830
        • Lecznica MAK-MED, NZOZ
      • Poznan, Poland, 61-397
        • Prywatna Praktyka Lekarska
      • Warszawa, Poland, 02-106
        • MTZ Clinical Research Sp. z o.o.
      • Warszawa, Poland, 01192
        • Synexus Polska Sp. z o.o. Oddzial w Warszawie
      • Wroclaw, Poland, 50-088
        • Synexus Polska Sp. Z O.O. Oddzial We Wroclawiu
    • Malopolska
      • Krakow, Malopolska, Poland, 30-002
        • Medica Pro Familia Sp. z o.o. S.K.A. Oddzial Krakow
    • WOJ Mazowieckie
      • Warszawa, WOJ Mazowieckie, Poland, 01-518
        • Centrum Medyczne AMED
  • Romania
      • Bucuresti, Romania, 011172
        • Spitalul Clinic Sf. Maria
      • Bucuresti, Romania, 010976
        • Ianuli Med Consult SRL, Reumatologie
      • Bucuresti, Romania, 011172
        • Spitalul Clinic Sf. Maria, Medicina interna - Reumatologie
      • Bucuresti, Romania, 020475
        • Spitalul Clinic "Dr. I. Cantacuzino"
      • Bucuresti, Romania, 020983
        • Centrul Clinic de Boli Reumatismale "Dr. Ion Stoia"
      • Galati, Romania, 800578
        • Spitalul Clinic Judetean de Urgenta - "Sf.Apostol Andrei" Galati
      • Iasi, Romania, 700661
        • Spitalul Clinic de Recuperare Iasi
    • Cluj
      • Cluj Napoca, Cluj, Romania, 400006
        • Spitalul Clinic Judetean de Urgenta Cluj Napoca Reumatologie
    • Covasna
      • Sfantu Gheorghe, Covasna, Romania, 520052
        • Covamed Serv SRL
    • Maramures
      • Baia Mare, Maramures, Romania, 430031
        • Spitalul Judetean de Urgenta "Dr. Constantin Opris"
      • Baia Mare, Maramures, Romania, 430352
        • S.C. Clinica Somesan S.R.L.
  • Russian Federation
      • Kemerovo, Russian Federation, 650066
        • SAHI of KR "Kemerovo Regional Clinical Hospital"
      • Moscow, Russian Federation, 119991
        • SBEI HPE First Moscow State Medical University n.a.I.M.Sechenov of MoH of RF based on UCH#1
      • Moscow, Russian Federation, 129090
        • CJSC "European Medical Center"
      • Novosibirsk, Russian Federation, 630102
        • SBEI HPE Novosibirsk State Medical University of MoH of RF
      • Orenburg, Russian Federation, 460018
        • State Budgetary Healthcare Institution "Orenburg Regional Clinical Hospital"
      • Ryazan, Russian Federation, 390026
        • State Budgetary Institution of Ryazan Region "Regional Clinical Cardiology Dispensary"
      • Saint Petersburg, Russian Federation, 191014
        • Limited Liability Company AVA-PETER
      • Samara, Russian Federation, 443095
        • State Budgetary Institution of Healthcare "Samara Regional Clinical Hospital n.a. V.D. Seredavin"
      • Saratov, Russian Federation, 410053
        • State Institution of Healthcare "Regional Clinical Hospital"
      • Smolensk, Russian Federation, 214025
        • Non-state Healthcare Institution "Regional Hospital at Smolensk Station of OJSC "Russian Railways"
      • Yaroslavl, Russian Federation, 150003
        • State Autonomous Healthcare lnstitution of Yarostavl Region
      • Yaroslavl, Russian Federation, 150007
        • State Budgetary Healthcare Institution of Yaroslavl Region "Clinical Hospital #3"
    • Karelia Republic
      • Petrozawodsk, Karelia Republic, Russian Federation, 185019
        • Republic Hospital n.a. V.A. Baranov
      • Petrozawodsk, Karelia Republic, Russian Federation, 185019
        • State Budgetary Healthcare Institution of Karelia Republic "Republic Hospital n.a. V.A. Baranov"
  • South Africa
    • FREE State
      • Bloemfontein, FREE State, South Africa, 9301
        • Iatros International
    • Gauteng
      • Johannesburg, Gauteng, South Africa, 2021
        • LCS Clinical Research Unit
      • Johannesburg, Gauteng, South Africa, 2193
        • WCR: Wits Clinical Research Charlotte Maxeke Johannesburg Academic Hospital
      • Johannesburg, Gauteng, South Africa, 2193
        • WCR: Wits Clinical Research
      • Parktown, Johannesburg, Gauteng, South Africa, 2193
        • Charlotte Maxeke Johannesburg Academic Hospital
      • Pretoria, Gauteng, South Africa, 0002
        • University Of Pretoria
      • Pretoria, Gauteng, South Africa, 0002
        • Clinical Research Unit, University of Pretoria
      • Pretoria, Gauteng, South Africa, 0002
        • Netcare Jakaranda Hospital
    • Kwazulu-natal
      • Durban, Kwazulu-natal, South Africa, 4001
        • Netcare St Augustine's Hospital
    • Western CAPE
      • Cape Town, Western CAPE, South Africa, 7405
        • Arthritis Clinical Research Trials
      • Cape Town, Western CAPE, South Africa, 7500
        • Panorama Medical Centre
      • Stellenbosch, Western CAPE, South Africa, 7600
        • Wineland Medical Research Centre
  • Spain
      • A Coruna, Spain, 15006
        • Complexo Hospitalario Universitario A Coruña
      • Barcelona, Spain, 08036
        • Hospital Clinic de Barcelona
      • Madrid, Spain, 28040
        • Hospital Universitario Fundacion Jimenez Diaz
      • Malaga, Spain, 29009
        • Hospital Regional Universitario de Malaga
      • Sevilla, Spain, 41010
        • Hospital Infanta Luisa
    • A Coruna
      • Santiago de Compostela, A Coruna, Spain, 15706
        • Complejo Hospitalario Universitario de Santiago de Compostela, Hospital Clinico Universitario
  • Taiwan
      • Hualien, Taiwan, 97002
        • Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
      • Kaohsiung, Taiwan, 81362
        • Kaohsiung Veterans General Hospital
      • Kaohsiung, Taiwan, 807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital - New
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
      • Taoyuan County, Taiwan, 33305
        • Chang Gung Medical Foundation - Linkou Branch
    • Taiwan ROC
      • Taichung, Taiwan ROC, Taiwan, 402
        • Chung Shan Medical University Hospital
  • Thailand
      • Bangkok, Thailand, 10700
        • Siriraj Hospital Mahidol University
      • Bangkok, Thailand, 10400
        • Cardiology Unit,Department of Medicine, Faculty of Medicine, Ramathibodi Hospital,Mahidol University
      • Bangkok, Thailand, 10400
        • Div. of Allergy Immunology and Rheumatology, Dept. of Medicine,
      • Songkhla, Thailand, 90110
        • Songklanagarind Hospital - Prince of Songkhla University
    • Rajthevi
      • Bangkok, Rajthevi, Thailand, 10400
        • Phramongkutklao Hospital
  • Turkey
      • Ankara, Turkey, 06100
        • Ankara Universitesi Tip Fakültesi Ibn-i Sina Hastanesi
      • Samsun, Turkey, 55139
        • Ondokuz Mayis Universitesi Tip Fakultesi Saglik Uyg. ve Eg.
      • Samsun, Turkey, 55139
        • Ondokuz Mayis Universitesi Tip Fakultesi Saglik Uygulama ve Egitim Merkezi
      • Sivas, Turkey, 58140
        • Cumhuriyet Universitesi Tip Fakultesi Hastanesi
  • United Kingdom
      • Cannock, United Kingdom, WS11 5XY
        • The Royal Wolverhamptons NHS Trust
      • Leeds, United Kingdom, LS7 4SA
        • The Leeds Teaching Hospitals NHS Trust
      • Liverpool, United Kingdom, L9 7AL
        • Aintree University Hospital NHS Foundation Trust
      • London, United Kingdom, NW3 2QG
        • Royal Free London NHS Foundation Trust
    • WEST Midlands
      • Dudley, WEST Midlands, United Kingdom, DY1 2HQ
        • The Dudley Group NHS Foundation Trust
  • United States
    • Alabama
      • Huntsville, Alabama, United States, 35801
        • Rheumatology Associates of North Alabama, PC
    • Arizona
      • Gilbert, Arizona, United States, 85234
        • Arthrocare, Arthritis Care & Research, PC
    • California
      • Covina, California, United States, 91722
        • Medvin Clinical Research
      • Fullerton, California, United States, 92835
        • St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare
      • Huntington Beach, California, United States, 92646
        • HealthCare Partners Medical Group
      • Los Angeles, California, United States, 90095
        • UCLA David Geffen School of Medicine, Division of Rheumatology
      • Los Angeles, California, United States, 90033
        • University of Southern California (USC) Norris Comprehensive Cancer Center
      • Los Angeles, California, United States, 90033
        • Keck Medicine of USC - Division of Rheumatology
      • Los Angeles, California, United States, 90095
        • Ronald Reagan UCLA Medical Center - Drug Information Center
      • Placentia, California, United States, 92870
        • Medvin Clinical Research
      • San Diego, California, United States, 92108
        • San Diego Arthritis Medical Clinic
      • Upland, California, United States, 91786
        • Inland Rheumatology Clinical Trials, Inc.
      • Van Nuys, California, United States, 91405
        • Medvin Clinical Research
      • Whittier, California, United States, 90602
        • Medvin Clinical Research
    • Connecticut
      • Bridgeport, Connecticut, United States, 06606
        • Joao M. A. Nascimento
    • Florida
      • Aventura, Florida, United States, 33180
        • Arthritis and Rheumatic Disease Specialties
      • Aventura, Florida, United States, 33180
        • AARDS Research, Inc.
      • Edgewater, Florida, United States, 32132
        • Riverside Clinical Research
      • Fort Lauderdale, Florida, United States, 33309
        • Centre for Rheumatology, Immunology and Arthritis
      • Jacksonville, Florida, United States, 32216
        • Jacksonville Center for Clinical Research
      • Orlando, Florida, United States, 32804
        • Omega Research Consultants, LLC
      • Palm Harbor, Florida, United States, 34684
        • Arthritis Center, Inc.
      • Pensacola, Florida, United States, 32514
        • Gulf Region Clinical Research Institute Llc
      • Tamarac, Florida, United States, 33321
        • West Broward Rheumatology Associates, Inc.
      • Tampa, Florida, United States, 33614
        • BayCare Medical Group Inc
      • Vero Beach, Florida, United States, 32960
        • The Center for Arthritis and Rheumatism
      • Vero Beach, Florida, United States, 32960
        • The Office of Alastair C. Kennedy, MD
      • Winter Garden, Florida, United States, 34787
        • Advanced Clinical Research of Orlando, Inc.
    • Idaho
      • Coeur d'Alene, Idaho, United States, 83814
        • Coeur D'Alene Arthritis Clinic
      • Idaho Falls, Idaho, United States, 83404
        • Institute of Arthritis Research
    • Illinois
      • Vernon Hills, Illinois, United States, 60061
        • Deerbrook Medical Associates
    • Indiana
      • Indianapolis, Indiana, United States, 46227
        • Diagnostic Rheumatology and Research PC
    • Louisiana
      • Baton Rouge, Louisiana, United States, 70809
        • Ochsner Clinic Baton Rouge
      • Monroe, Louisiana, United States, 71203
        • Arthritis and Diabetes Clinic, Inc
    • Maryland
      • Frederick, Maryland, United States, 21702
        • Arthritis Treatment Center
    • Michigan
      • Kalamazoo, Michigan, United States, 49007
        • Jasper Clinic
    • Mississippi
      • Flowood, Mississippi, United States, 39232
        • Arthritis and Osteoporosis Treatment and Research Center
    • Missouri
      • Saint Louis, Missouri, United States, 63128
        • St. Louis Center For Clinical Research Barbara Caciolo, MD
      • Springfield, Missouri, United States, 65807
        • Clinvest/ A Division Of Banyan Group, Inc.
    • New York
      • Plainview, New York, United States, 11803
        • Dr. Prem C. Chatpar M.D.,LLC
    • North Carolina
      • Salisbury, North Carolina, United States, 28144
        • PMG Research of Salisbury, LLC
      • Salisbury, North Carolina, United States, 28144
        • Rowan Diagnostic Clinic
      • Wilmington, North Carolina, United States, 28401
        • PMG Research of Wilmington
    • North Dakota
      • Minot, North Dakota, United States, 58701
        • Trinity Health Center - Medical Arts
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73112
        • Lynn Health Science Institute
    • Pennsylvania
      • Duncansville, Pennsylvania, United States, 16635
        • Altoona Center For Clinical Research
      • Philadelphia, Pennsylvania, United States, 19152-3303
        • Arthritis Group
    • South Carolina
      • Charleston, South Carolina, United States, 29406
        • Low Country Rheumatology, PA
    • Tennessee
      • Jackson, Tennessee, United States, 38305
        • West Tennessee Research Institute
    • Texas
      • Baytown, Texas, United States, 77521
        • Accurate Clinical Management, LLC
      • Dallas, Texas, United States, 75231
        • Metroplex Clinical Research Center
      • Dallas, Texas, United States, 75231
        • Arthritis Care And Diagnostic Center, P.A.
      • Houston, Texas, United States, 77074
        • Houston Institute For Clinical Research
      • Houston, Texas, United States, 77004
        • Accurate Clinical Management, LLC
      • Houston, Texas, United States, 77065
        • Rheumatology Clinic of Houston, PA
      • Lubbock, Texas, United States, 79424
        • Arthritis & Osteoporosis Associates, LLP
      • Mesquite, Texas, United States, 75150
        • Southwest Rheumatology Research, LLC.
      • San Antonio, Texas, United States, 78229
        • Accurate Clinical Research, Inc.
      • San Antonio, Texas, United States, 78232
        • Arthritis & Osteoporosis Center of South Texas
    • Washington
      • Spokane, Washington, United States, 99204
        • Arthritis Northwest, PLLC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Have moderate to severe rheumatoid arthritis
  • On methotrexate but inadequately controlled
  • Subjects must not have active tuberculosis or an inadequately treated tuberculosis infection
  • Subjects must use contraception

Exclusion Criteria:

  • Subjects who have been previously treated with adalimumab or Tofacitinib
  • Subjects with any current malignancy or a history of malignancy, with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
  • Subjects with specific laboratory test abnormalities
  • Subjects with specific types of infections

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Tofacitinib 5 mg twice daily with methotrexate
Drug: Tofacitinib with methotrexate
Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Experimental: Tofacitinib 5 mg twice daily monotherapy
Drug: Tofacitinib without methotrexate
Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Active Comparator: Adalimumab with methotrexate
Biological: Adalimumab with methotrexate
Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6
Time Frame: Month 6
ACR50 is a greater than or equal to (≥) 50 percent (%) improvement in tender joint count (TJC) or swollen joint count (SJC) and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment (PGA) of disease activity, 2) participant's assessment (PtGA) of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein (CRP) at each visit.
Month 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Simplified Disease Activity Index (SDAI) Value at Month 6
Time Frame: Month 6
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 centimeter (cm) visual analogue scale (VAS) (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI less than or equal to (≤) 3.3 indicates disease remission, >3.4 to 11 indicates low disease activity, >11 to 26 indicates moderate disease activity, and >26 indicates high disease activity.
Month 6
Change From Baseline in Clinical Disease Activity Index (CDAI) Value at Month 6
Time Frame: Month 6
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, >2.8 to 10 indicates low disease activity, >10 to 22 indicates moderate disease activity, and >22 indicates high disease activity.
Month 6
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including CRP at Month 6
Time Frame: Month 6
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA (millimeters [mm]) + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity, >3.2 to 5.1 indicates moderate to high disease activity, and less than (<) 2.6 indicates remission.
Month 6
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including Erythrocyte Sedimentation Rate (ESR) at Month 6
Time Frame: Month 6
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-3 (ESR) ≤3.2 indicates low disease activity, >3.2 to 5.1 indicates moderate to high disease activity, and <2.6 indicates remission.
Month 6
Percentage of Participants Achieving Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria at Month 6
Time Frame: Month 6
To meet the ACR-EULAR Boolean remission criteria, a participant must satisfy all of the following: TJC ≤1 and SJC ≤1 (both based on a 28-joint assessment), CRP ≤1 mg/dL, and PtGA ≤1 on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity).
Month 6
Percentage of Participants Achieving SDAI ≤3.3 at Month 6
Time Frame: Month 6
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission.
Month 6
Percentage of Participants Achieving CDAI ≤2.8 at Month 6
Time Frame: Month 6
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission.
Month 6
Percentage of Participants Achieving DAS28-4 (ESR) <2.6 at Month 6
Time Frame: Month 6
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) <2.6 indicates disease remission.
Month 6
Percentage of Participants Achieving DAS28-4 (CRP) <2.6 at Month 6
Time Frame: Month 6
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA (mm) + 0.96. Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (CRP) <2.6 indicates remission.
Month 6
Percentage of Participants Achieving SDAI ≤11 at Month 6
Time Frame: Month 6
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission, >3.4 to 11 indicates low disease activity.
Month 6
Percentage of Participants Achieving CDAI ≤10 at Month 6
Time Frame: Month 6
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, >2.8 to 10 indicates low disease activity.
Month 6
Percentage of Participants Achieving DAS28-4 (ESR) ≤3.2 at Month 6
Time Frame: Month 6
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) ≤3.2 indicates low disease activity.
Month 6
Percentage of Participants Achieving DAS28-4 (CRP) ≤3.2 at Month 6
Time Frame: Month 6
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity.
Month 6
Percentage of Participants Achieving American College of Rheumatology Criteria 20% Improvement (ACR20) Response at Month 6
Time Frame: Month 6
ACR20 response is a ≥20% improvement in TJC or SJC and 20% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.
Month 6
Percentage of Participants Achieving American College of Rheumatology Criteria 70% Improvement (ACR70) Response at Month 6
Time Frame: Month 6
ACR70 response is a ≥70% improvement in TJC or SJC and 70% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.
Month 6
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Month 6
Time Frame: Month 6
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty.
Month 6
Percentage of Participants Achieving an HAQ-DI Decrease of at Least 0.22 at Month 6
Time Frame: Month 6
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. A decrease of 0.22 or more is considered a positive response.
Month 6
Change From Baseline in the Short-Form-36 (SF-36) Health Survey, Physical Component Score at Month 6
Time Frame: Month 6
The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based scores for both the SF-36 version 2 (v2) and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status.
Month 6
Change From Baseline in the SF-36 Health Survey, Mental Component Score at Month 6
Time Frame: Month 6
The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better physical health status.
Month 6
Change From Baseline in the SF-36 Health Survey, Physical Functioning Domain Score at Month 6
Time Frame: Month 6
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 10 items of the physical functioning scale represent levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher physical functioning domain score represents better physical functioning.
Month 6
Change From Baseline in the SF-36 Health Survey, Role Physical Domain Score at Month 6
Time Frame: Month 6
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item role physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; and d) accomplishing less. Items in the role physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role physical domain score represents better role physical functioning.
Month 6
Change From Baseline in the SF-36 Health Survey, Bodily Pain Domain Score at Month 6
Time Frame: Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher bodily pain domain score represents less bodily pain.
Month 6
Change From Baseline in the SF-36 Health Survey, General Health Domain Score at Month 6
Time Frame: Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher general health domain score represents better general health perceptions.
Month 6
Change From Baseline in the SF-36 Health Survey, Vitality Domain Score at Month 6
Time Frame: Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher vitality domain score represents better vitality.
Month 6
Change From Baseline in the SF-36 Health Survey, Social Functioning Domain Score at Month 6
Time Frame: Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher social functioning domain score represents better social functioning.
Month 6
Change From Baseline in the SF-36 Health Survey, Role Emotional Domain Score at Month 6
Time Frame: Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 3-item role emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role emotional domain score represents better role emotional functioning.
Month 6
Change From Baseline in the SF-36 Health Survey, Mental Health Domain Score at Month 6
Time Frame: Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher mental health domain score represents better mental health functioning.
Month 6
Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire at Month 6
Time Frame: Month 6
The WPAI: Rheumatoid Arthritis is a 6 item questionnaire that is specific for rheumatoid arthritis and yields four types of scores: absenteeism, presenteesism (impairment at work/reduced job effectiveness), work productivity loss and activity impairment. WPAI outcomes are expressed as impairment percentages ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity.
Month 6
Change From Baseline in the EuroQol European Quality of Life-5 Dimensions (EuroQol EQ-5D) at Month 6
Time Frame: Month 6
The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). This profile of scores across the 5-dimensions (e.g. 11231, 33212, etc.) is transformed into a single health utility score using a formula developed by the EuroQol Group that applies country specific preference weights. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rated the current health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicating a better health state.
Month 6
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Total Score at Month 6
Time Frame: Month 6
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). The larger the participant's response (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).
Month 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pfizer

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2014

Primary Completion (Actual)

December 1, 2016

Study Completion (Actual)

December 1, 2016

Study Registration Dates

First Submitted

July 8, 2014

First Submitted That Met QC Criteria

July 8, 2014

First Posted (Estimate)

July 10, 2014

Study Record Updates

Last Update Posted (Actual)

June 27, 2018

Last Update Submitted That Met QC Criteria

May 29, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A3921187
  • 2014-000358-13 (EudraCT Number)
  • ORAL STRATEGY (Other Identifier: Alias Study Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rhematoid Arthritis

Clinical Trials on Tofacitinib with methotrexate

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe